SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Metastatic Castration Resistant Prostate Cancer Clinical Trial

— mCRPC  

Official title:

Sc10914 Monotherapy for Metastatic Castration Resistant Prostate Cancer Patients With Germ and / or Somatic BRCA Mutation: a Single Arm, Multicenter Clinical Tria

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04486937
• Other study ID #: QF-SC10914-202
• Status: Not yet recruiting
• Phase: Phase 1/Phase 2
• Start date: August 30, 2020
• Est. completion date: June 30, 2022

Study information

• Verified date: July 2020
• Source: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Contact: Yuping Zhang
• Phone: 18010196244
• Email: zhangyuping[@]sh-qingfeng.net
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multicenter, single arm phase I / II clinical study in mCRPC subjects who failed to receive docetaxel chemotherapy, abitolone acetate and / or enzalutamide (including its analogues) for the treatment of BRCA mutations in germ cells and / or somatic cells.

Description:

The subjects oral administration sc10914 tablets 400mg on an empty stomach, three times a day, for 28 consecutive days as a treatment cycle, until disease progression (PD) (according to Recist1.1 and the adjusted PCWG3 standard, the subjects met the imaging [CT / MRI / bone scan] PD standard) or the toxicity was intolerable.

The study is divided into two stages: in the first stage,enrolled 36 patients whose response can be evaluated, if there are at least 7 cases of objective remission (CR or PR), the second stage is allowed, otherwise the study will be stopped; in the second stage, the number of subjects whose response can be evaluated is planned to continue to be enrolled to 70 cases（stage 1 and stage 2）.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: June 30, 2022
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signing informed consent voluntarily;

2. Prostate cancer confirmed by histology or cytology;

3. Metastatic lesions proved by imaging (CT / MRI / bone scan);

4. At least one measurable lesion in accordance with recist1.1;

5. deleterious or suspected deleterious germline and/or somatic BRCA-mutated (g/sBRCAm)

6. ECOG=2;

7. The expected survival time was more than 3 months;

8. Serum testosterone levels = 50 ng/dL (= 1.75 nmol/L) at screening.

9. Subjects without prior surgical castration must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analog (agonist or antagonist) therapy throughout the duration of study treatment.

9.Subjects must have progressed on prior NHA (e.g. abiraterone acetate and/or enzalutamide) for the treatment of mCRPC. 10.Subjects must have progressed on prior chemotherapy with docetaxel for the treatment of mCRPC.

Exclusion Criteria:

1. Any previous treatment with PARP inhibitor

2. Concomitant use of known strong CYP3A inhibitors or moderate CYP3A inhibitors. The required washout period prior to starting olaparib is 2 weeks or 5 half-life.

3. Subjects with known brain metastases.

4. Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery

5. Subjects unable to swallow orally administered medication and subjects with gastrointestinal disorders likely to interfere with Absorption, distribution, metabolism and excretion of the study

6. Immunocompromised subjects, e.g., subjects who are known to be serologically positive for human immunodeficiency virus (HIV)

7. Subjects with a known hypersensitivity to SC10914 or any of the excipients of the product

8. Subjects with known active hepatitis (i.e. Hepatitis B or C)

9. Subjects with not enough organ functional reserve at baseline, which met at least one of the following criteria:

1. ANC<1.5×109/L;

2. PLT<100×109/L;

3. Hb<100g/L;

4. TBIL>1.5×ULN;

5. ALT?AST>2.5×ULN unless liver metastases are present in which case they must be > 5×ULN;

6. Cr >1.5×ULN?

10. Subjects who have impaired cardiac function or clinically significant cardiac diseases, including any of the following:

1. Baseline QT interval corrected for heart rate (HR) using Fridericia's formula >500 msec or congenital long QT syndrome;

2. Left ventricular ejection fraction (LVEF) <50% assessed by echocardiogram;

3. Other clinically significant heart disease such as congestive heart failure NYHA Class IV and requiring heart transplant

11. Severe bone injury caused by tumor bone metastases as judged by the researchers, including severe bone pain due to poor control, pathological fracture of important parts or spinal cord compression occurred or expected to occur in the near future in the last 6 months.

Related Conditions & MeSH terms

• Metastatic Castration Resistant Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• S410914 tablet
S410914 tablet

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Jiangxi Qingfeng Pharmaceutical Co. Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	objective response rate (ORR)	assessed by the independent imaging assessment committee (recist1.1)	up to 100 weeks (estimated)
Secondary	PFS		up to 100 weeks (estimated)
Secondary	Disease control rate (DCR), duration of response (DOR), time to tumor progression (TTP)	evaluated according to recist1.1 and adjusted pcwg3 criteria	up to 100 weeks (estimated)
Secondary	overall survival (OS)	evaluated according to recist1.1 and adjusted pcwg3 criteria	up to 100 weeks (estimated)